Regeneron Pharmaceuticals Inc. recently held its Q2 2025 earnings conference call, with key executives including Dr. Leonard Schleifer, Co-Chair, Co-Founder, President, and CEO; Dr. George Yancopoulos, Co-Chair, Co-Founder, President, and Chief Scientific Officer; Marion McCourt, Executive Vice President of Commercial; and Chris Fenimore, Executive Vice President and CFO, participating in the event. The call, which took place on August 1, 2025, covered a range of topics, notably financial forecasting guidance, development programs, and regulatory matters. During the call, management emphasized the importance of forward-looking statements and acknowledged the risks and uncertainties that could affect actual results. They noted, "Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially." The discussion also included the use of GAAP and non-GAAP financial measures, with further information available in the company's quarterly results press release and corporate presentation. The investor relations team remains available to address any additional questions. The full transcript can be accessed through the link below.